title: Fragmenting the platelet to reduce metastasis.
abstract: In this issue of Blood, Zhang et al describe an antiplatelet reagent attacking metastasis, the most deadly aspect of cancer.(1) Their experiments outline an early-stage preclinical approach providing proof-of-principle for antiplatelet strategies that may ultimately lead to an improved prognosis for the cancer patient.(1)
authors.affiliation: University of Arkansas for Medical Sciences, AR, USA.
authors.forename: Jerry
authors.initials: J
authors.lastname: Ware
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008546:Melanoma, Experimental / Q000517:prevention & control*; D015539:Platelet Activation / Q000276:immunology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000276:immunology*; D057127:Single-Chain Antibodies / Q000627:therapeutic use*; D059016:Tumor Microenvironment / Q000276:immunology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D057127:Single-Chain Antibodies